Results 191 to 200 of about 11,212 (232)
Some of the next articles are maybe not open access.
JAMA, 1964
A CAREFULLY CONDUCTED CLINICAL TRIAL is the most efficient means by which to determine the usefulness of a particular treatment in a particular disease. Sometimes a treatment is so obviously effective that a clinical trial serves primarily to establish its usefulness relative to other treatments and to the severity of disease.
openaire +2 more sources
A CAREFULLY CONDUCTED CLINICAL TRIAL is the most efficient means by which to determine the usefulness of a particular treatment in a particular disease. Sometimes a treatment is so obviously effective that a clinical trial serves primarily to establish its usefulness relative to other treatments and to the severity of disease.
openaire +2 more sources
Update on Ocular Myasthenia Gravis
Seminars in Neurology, 2019AbstractMyasthenia gravis is an antibody-mediated autoimmune disorder of the post-synaptic neuromuscular junction resulting in fluctuating, fatigable weakness. Most patients first present with extraocular symptoms (diplopia and/or ptosis), and in 15% of cases symptoms will remain restricted to only the extraocular muscles (ocular myasthenia gravis [OMG]
Meabh, O'Hare, Christopher, Doughty
openaire +2 more sources
Current Opinion in Ophthalmology, 1996
Ocular myasthenia gravis may mimic any pupil-spared, painless, nonproptotic ophthalmoplegia with or without ptosis. This review references recent papers regarding clinical features, diagnostic techniques, and treatment for ocular myasthenia gravis.
openaire +2 more sources
Ocular myasthenia gravis may mimic any pupil-spared, painless, nonproptotic ophthalmoplegia with or without ptosis. This review references recent papers regarding clinical features, diagnostic techniques, and treatment for ocular myasthenia gravis.
openaire +2 more sources
Childhood ocular myasthenia gravis
Ophthalmology, 2003To investigate the clinical manifestations and ocular findings in children with ocular myasthenia gravis (MG) that rarely have been reported in the literature.Retrospective, noncomparative case series.Twenty-four consecutive patients less than 15 years of age with ocular MG treated between June 1988 and July 2001.The medical records of 6 boys and 18 ...
Jong-Hyun, Kim +4 more
openaire +2 more sources
Treatment of Ocular Myasthenia Gravis
Current Treatment Options in Neurology, 2011Myasthenia gravis (MG) is an autoimmune disorder that is characterized by variable weakness and fatigability. Often, MG presents with only ocular symptoms such as ptosis and diplopia. Treatment of ocular MG is aimed at relieving the symptoms of ptosis and diplopia, as well as preventing the development of generalized MG symptoms.
Scott R, Haines, Matthew J, Thurtell
openaire +2 more sources
2019
Ocular myasthenia typically causes intermittent or fluctuating ptosis and diplopia yet can be difficult to diagnose definitively. In this chapter, we begin by reviewing the symptoms and signs of ocular myasthenia. We next discuss the laboratory workup for antibodies that are associated with ocular myasthenia and describe bedside tests that can helpful ...
Matthew J. Thurtell, Robert L. Tomsak
openaire +1 more source
Ocular myasthenia typically causes intermittent or fluctuating ptosis and diplopia yet can be difficult to diagnose definitively. In this chapter, we begin by reviewing the symptoms and signs of ocular myasthenia. We next discuss the laboratory workup for antibodies that are associated with ocular myasthenia and describe bedside tests that can helpful ...
Matthew J. Thurtell, Robert L. Tomsak
openaire +1 more source
2011
Ocular myasthenia typically causes intermittent or fluctuating ptosis and diplopia but is often difficult to diagnose definitively. We discuss the approach to the patient with suspected ocular myasthenia but no acetylcholine-receptor antibodies, and review the treatment options for ocular myasthenia.
Matthew J. Thurtell +2 more
openaire +1 more source
Ocular myasthenia typically causes intermittent or fluctuating ptosis and diplopia but is often difficult to diagnose definitively. We discuss the approach to the patient with suspected ocular myasthenia but no acetylcholine-receptor antibodies, and review the treatment options for ocular myasthenia.
Matthew J. Thurtell +2 more
openaire +1 more source
Pediatric Ocular Myasthenia Gravis
Current Treatment Options in Neurology, 2019We present a review of current strategies in the treatment of pediatric ocular myasthenia gravis (OMG). A critical appraisal was performed of the current literature available on OMG and the treatment options available for all age populations. From this data, we present the evidence surrounding therapeutic options for pediatric OMG and discuss treatment
Kristen, Fisher, Veeral, Shah
openaire +2 more sources
Mycophenolate mofetil for ocular myasthenia
Journal of Neurology, 2008To study the safety and tolerability of mycophenolate mofetil (MM), since this steroid-sparing immunomodulatory agent with less side effects, compared to corticosteroids, may be considered for long-term management of ocular myasthenia (OMG).Consecutive patients with OMG started on MM between December 2000 and December 2002 were followed up to December ...
openaire +2 more sources
JAMA, 1982
OCULAR myasthenia is a wellknown, localized form of myasthenia gravis frequently limited to the extraocular muscles. It occurs in 20% to 25% of adult patients with this disorder. 1,2 A patient with ocular myasthenia in whom multiple brief recurrences were each followed by rapid spontaneous remission lasting several years is the subject of this report.
openaire +2 more sources
OCULAR myasthenia is a wellknown, localized form of myasthenia gravis frequently limited to the extraocular muscles. It occurs in 20% to 25% of adult patients with this disorder. 1,2 A patient with ocular myasthenia in whom multiple brief recurrences were each followed by rapid spontaneous remission lasting several years is the subject of this report.
openaire +2 more sources